DURHAM, N.C., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that it will host a Key Opinion Leader breakfast focused on current advances in bladder cancer immunotherapy. The event and live webcast will take place on Thursday, February 26 from 8:00am-9:30am Eastern Time in New York City.
The meeting will feature a medical expert and key opinion leader on bladder cancer from a leading academic institution who will discuss current advances in bladder cancer immunotherapy. Senior members of the Heat Biologics executive management team, including Jeff Wolf, CEO, Taylor Schreiber, M.D., Ph.D., Vice President of Research and Development and Melissa Price, Ph.D., Vice President of Clinical and Regulatory Affairs will provide an overview of the Company's technology and ongoing clinical development work with vesigenurtacel-L (HS-410) in non-muscle invasive bladder cancer. They will be available for Q&A.
The event is intended for institutional investors and sell-side analysts only. To reserve a place, please contact Veronica Molina at 212-915-2567 or via e-mail at email@example.com. A live webcast and subsequent replay of the event will also be available to the public at http://lifesci.rampard.com/20150226/reg.jsp, and will also be accessible through the Investors section of the Company's website at www.heatbio.com.
About Heat Biologics, Inc.
Heat Biologics, Inc. (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial of its viagenpumatucel-L (HS-110) in patients with non-small cell lung cancer as well as a Phase 2 trial with its vesigenurtacel-L (HS-410) in patients with non-muscle invasive bladder cancer.
Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential for impact of Heat's ImPACT Therapy. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat's ImPACT Therapy to perform as designed and the other factors described in our annual report on Form 10-K for the year ended December 31, 2013 and our other filings with the SEC. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
CONTACT: Heat Biologics, Inc. Contact Information: Jeff Wolf Chief Executive Officer (919) 240-7133 firstname.lastname@example.org Investor Relations Michael Wood LifeSci Advisors LLC (646) 597-6983 email@example.com